Lacosamide: Pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures

Expert Review of Neurotherapeutics

Volumn 9, Issue 1, 2009, Pages 33-42

  Beydoun, Ahmad ^a   D'Souza, Joseph ^b   Hebert, David ^b   Doty, Pamela ^b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UCB PHARMA   (Belgium)

Author keywords

Antiepileptic; Clinical trial; Lacosamide; Partial onset seizure; Pooled analysis

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; COLLAPSIN RESPONSE MEDIATOR PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; DIGOXIN; ETHOSUXIMIDE; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; METFORMIN; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PLASMA PROTEIN; SODIUM CHANNEL BLOCKING AGENT; TOPIRAMATE; VALPROIC ACID; VOLTAGE GATED SODIUM CHANNEL; ZONISAMIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ATRIOVENTRICULAR BLOCK; BALANCE DISORDER; BILIRUBIN BLOOD LEVEL; BLURRED VISION; BODY WEIGHT; CLONIC SEIZURE; COGNITIVE DEFECT; COORDINATION DISORDER; DIPLOPIA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; EPILEPTIC STATE; EVENING DOSAGE; FATIGUE; FOCAL EPILEPSY; HEADACHE; HUMAN; MOOD DISORDER; MORNING DOSAGE; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PR INTERVAL; RASH; REVIEW; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SOMNOLENCE; TONIC CLONIC SEIZURE; TREMOR; VOMITING;

ACETAMIDES; ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; HUMANS; SEIZURES;

EID: 58149215498     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.9.1.33     Document Type: Review

References (30)

1. Hauser WA, Rich SS, Annegers JF, Anderson VE. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up. Neurology 40(8), 1163-1170 (1990).
2. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 42(10), 1255-1260 (2001).
3. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med. 342(5), 314-319 (2000).
4. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48(7), 1308-1317 (2007).
5. Beyreuther BK, Freitag J, Heers C, Krebsfänger N, Scharfenecker U, Stöhr T. Lacosamide: a review of preclinical properties. CNS Drug Rev. 13(1), 21-42 (2007).
6. Errington AC, Coyne L, Stöhr T, Selve N, Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 50(8), 1016-1029 (2006).
7. Errington AC, Stöhr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol. 3(1), 157-169 (2008).
8. + channels. Mol. Pharmacol. 4, 712-721 (1998).
9. Rudy B. Slow inactivation of the sodium conductance in squid giant axons. Pronase resistance. J. Physiol. 283, 1-21 (1978).
10. Jung HY, Mickus T, Spruston N. Prolonged sodium channel inactivation contributes to dendritic action potential attenuation in hippocampal pyramidal neurons. J. Neurosci. 17(17), 6639-6646 (1997).
11. Mickus T, Jung HY, Spruston N. Slow sodium channel inactivation in CA1 pyramidal cells. Ann. NY Acad. Sci. 868, 97-101 (1999).
12. Yoshimura T, Arimura N, Kaibuchi K. Signaling networks in neuronal polarization. J. Neurosci. 26(42), 10626-10630 (2006).
13. Freitag J, Beyreuther BK, Heers C, Stöhr T. Lacosamide interacts with collapsin response mediator protein 2 (CRMP-2). Presented at: 11th Congress of the European Federation of Neurological Societies. Brussels, Belgium, 22-28 August 2008.
14. Cavazos JE, Cross DJ. The role of synaptic reorganization in mesial temporal lobe epilepsy. Epilepsy Behav. 8(3), 483-493 (2006).
15. Löscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 2(3), 145-181 (1988).
16. Barton ME, Klein BD, Wolf HH, White HS. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 47(3), 217-227 (2001).
17. Stöhr T, Kupferberg HJ, Stables JP et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 74(2-3), 147-154 (2007).
18. Duncan GE, Kohn H. The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model. Epilepsy Res. 67(1-2), 81-87 (2005).
19. Brandt C, Heile A, Potschka H, Stoehr T, Löscher W. Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 47(11), 1803-1809 (2006).
20. Hovinga CA. SPM-927 (Schwarz Pharma). IDrugs 6(5), 479-485 (2003).
21. Cawello W, Kropeit D, Schiltmeyer B, Hammes W, Horstmann R. Food does not affect the pharmacokinetics of SPM 927. Epilepsia 45(Suppl. 7), 307 (2004).
22. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 61(1-3), 1-48 (2004).
23. Horstmann R, Bonn R, Cawello W, Doty P, Rudd D. Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927. Epilepsia 43(Suppl. 7), 188 (2002).
24. Schiltmeyer B, Cawello W, Kropeit D, Hammes W, Horstmann R. Pharmacokinetics of the new antiepileptic drug lacosamide in human subjects with different age and gender. Presented at: 58th Annual Meeting of the American Epilepsy Society. New Orleans, LA, USA, 3-7 December 2004.
25. Kropeit D, Schiltmeyer B, Cawello W, Hammes W, Horstmann R. Bioequivalence of short-time infusions compared to oral administration of SPM 927. Epilepsia 45(Suppl. 7), 123-124 (2004).
26. Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd GD. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 49(3), 418-424 (2008).
27. Krauss G, Ben Menachem E, Mameniskiene R, Vaiciene N, Rudd D, Brock M. Lacosamide: safety and tolerability of adjunctive intravenous lacosamide as short-term replacement for oral lacosamide in subjects with partial-onset seizures during 30-, 15-, and 10-minute infusions. Eur. J. Neurol. 14(Suppl. 1), 319-320 (2007).
28. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res. 73(1), 1-52 (2007).
29. Thomas D, Scharfenecker U, Nickel B, Doty P, Cawello W, Horstmann R. Lacosamide has low potential for drug-drug interaction. Presented at: 8th European Congress on Epileptology. Berlin, Germany, 21-25 September 2008.
30. Cramer JA, Ben Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res. 47(1-2), 17-25 (2001).